Cargando…
Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
PURPOSE: To evaluate the ocular hypotensive efficacy and safety of razuprotafib, a novel Tie2 activator, when used as an adjunct to latanoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: Subjects with OAG or OHT and an unmedicated IOP from ≥22 mm Hg to <36 m...
Autores principales: | Brigell, Mitchell, Withers, Barbara, Buch, Akshay, Peters, Kevin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742526/ https://www.ncbi.nlm.nih.gov/pubmed/34989803 http://dx.doi.org/10.1167/tvst.11.1.7 |
Ejemplares similares
-
A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure
por: Li, Guorong, et al.
Publicado: (2020) -
Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Shen Lee, Bridgitte, et al.
Publicado: (2022) -
Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
por: Konieczka, Katarzyna, et al.
Publicado: (2019) -
Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin
por: Frye, Maike, et al.
Publicado: (2015) -
VE-PTP controls blood vessel development by balancing Tie-2 activity
por: Winderlich, Mark, et al.
Publicado: (2009)